Acta Crystallographica Section E Structure Reports Online

ISSN 1600-5368

## Jian-Qiang Qu,<sup>a</sup>\* Ling Qu<sup>b</sup> and Xiao-Fei Jia<sup>a</sup>

<sup>a</sup>Department of Chemistry, Tianjin University, Tianjin 300072, People's Republic of China, and <sup>b</sup>Ningxia Academy of Agriculture and Forestry Sciences, Yinchuan 750002, People's Republic of China

Correspondence e-mail: jqqu@tju.edu.cn

#### **Key indicators**

Single-crystal X-ray study T = 294 K Mean  $\sigma$ (C–C) = 0.003 Å R factor = 0.041 wR factor = 0.121 Data-to-parameter ratio = 12.0

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

# 5-Fluorouracil-1-acetic acid

In the title compound,  $C_6H_5FN_2O_4$ , the acetic acid group lies out of the pyrimidine plane. In the crystal structure, molecules are connected by intermolecular  $N-H\cdots O$ ,  $O-H\cdots O$  and  $C-H\cdots O$  hydrogen bonds, forming a three-dimensional network.

#### Comment

The cycle-specific schedule-dependent antimetabolite 5fluorouracil has been used in clinics for 40 years and has evolved as an important agent in the treatment of a large spectrum of tumours, including breast cancer, gastric carcinoma and bladder cancer (Duschinsky *et al.*, 1957; Heidelberger *et al.*, 1957; Correale *et al.*, 2005). However, its slight harmfulness to the liver, kidney and digestive system limits its wider applicability (Wasterack & Bettina, 1987). For these reasons, many derivatives of 5-fluorouracil have been synthesized and some compounds have better biological activity. 5-Fluorouracil-1-acetic acid, (I), is a member of the family (Tada, 1975). Its metal complexes have been reported to have biological activity (Wang *et al.*, 1993; Qu *et al.*, 2001; Huang *et al.*, 2005).



The acetic acid group lies out of the pyrimidine plane (Fig. 1). The C-F, C-O and C-N bond distances are given in Table 1. In (I), there are intermolecular N-H···O, O-H···O and C-H···O hydrogen bonds (Table 2), forming a three-dimensional network (Fig. 2).

### **Experimental**

The title compound, (I), was prepared according to the literature method of Tada (1975). A mixture of 5-fluorouracil (5.2 g), chloroacetic acid (3.8 g), potassium hydroxide (4.48 g) and water (100 ml) was refluxed at 353 K for 2 h and cooled to room temperature. After the pH of the mixture was adjusted to 2 with hydrochloric acid, the title compound was obtained (yield 71%; m.p. 548–549 K). Single crystals suitable for X-ray diffraction were obtained by slow evaporation of an ethanol solution.

© 2006 International Union of Crystallography All rights reserved Received 4 March 2006

Accepted 15 March 2006

#### Crystal data

 $\begin{array}{l} C_{6}H_{5}FN_{2}O_{4}\\ M_{r} = 188.12\\ \text{Monoclinic, } P2_{1}/n\\ a = 4.9730 (10) \text{ Å}\\ b = 17.093 (3) \text{ Å}\\ c = 8.7485 (17) \text{ Å}\\ \beta = 97.424 (3)^{\circ}\\ V = 737.4 (2) \text{ Å}^{3}\\ Z = 4 \end{array}$ 

#### Data collection

Bruker SMART CCD area-detector diffractometer  $\varphi$  and  $\omega$  scans Absorption correction: multi-scan (*SADABS*; Sheldrick, 1996)  $T_{\min} = 0.963, T_{\max} = 0.972$ 4104 measured reflections

#### Refinement

#### Refinement on $F^2$ $R[F^2 > 2\sigma(F^2)] = 0.041$ $wR(F^2) = 0.121$ S = 1.031507 reflections 126 parameters H atoms treated by a mixture of independent and constrained refinement

Table 1		

Selected bond lengths (Å).

F1-C3	1.422 (2)	N1-C2	1.370 (3)
O1-C2	1.232 (2)	N1-C1	1.385 (3)
O2-C1	1.213 (2)	N2-C1	1.374 (2)
O3-C6	1.200(2)	N2-C4	1.376 (3)
O4-C6	1.322 (2)	N2-C5	1.461 (2)

 $D_x = 1.694 \text{ Mg m}^{-3}$ 

Cell parameters from 1757

Mo  $K\alpha$  radiation

reflections

 $\mu = 0.16 \text{ mm}^{-1}$ 

T = 294 (2) K

 $R_{\rm int} = 0.023$ 

 $\theta_{\rm max} = 26.4^{\circ}$ 

 $h = -6 \rightarrow 6$ 

 $k = -11 \rightarrow 21$ 

 $l = -10 \rightarrow 10$ 

Block, colourless

0.24  $\times$  0.20  $\times$  0.18 mm

1507 independent reflections

 $w = 1/[\sigma^2(F_0^2) + (0.0616P)^2]$ 

+ 0.3397*P*] where  $P = (F_0^2 + 2F_c^2)/3$ 

 $\Delta \rho_{\rm max} = 0.38 \text{ e } \text{\AA}^{-3}$ 

 $\Delta \rho_{\rm min} = -0.19 \text{ e } \text{\AA}^{-3}$ 

 $(\Delta/\sigma)_{\rm max} < 0.001$ 

1139 reflections with  $I > 2\sigma(I)$ 

 $\theta = 2.6 - 26.2^{\circ}$ 

Та	ble	2
	~	_

						0		
H١	ydrog	gen-	bond	geometry	y (1	Α,	0)	).

$D - H \cdots A$	D-H	$H \cdot \cdot \cdot A$	$D \cdots A$	$D - H \cdots A$
$O4-H4\cdots O1^{i}$	0.98 (3)	1.81 (3)	2.696 (2)	148 (3)
$N1-H1\cdots O1^{ii}$	0.91 (3)	2.00(3)	2.904 (2)	171 (2)
$C4-H4A\cdots O2^{iii}$	0.93	2.53	3.284 (3)	139
$C5-H5A\cdots O3^{iv}$	0.97	2.56	3.368 (2)	141
$C5-H5B\cdots O3^{v}$	0.97	2.50	3.459 (3)	172
Symmetry codes:	(i) $-x + \frac{1}{2}$ , y	$z - \frac{1}{2}, -z + \frac{1}{2};$	(ii) $-x + 1, -y$	+1, -z; (iii)

Symmetry codes: (i)  $-x + \frac{1}{2}, y - \frac{1}{2}, -z + \frac{1}{2};$  (ii)  $-x + 1, x - \frac{1}{2}, -y + \frac{1}{2}, z + \frac{1}{2};$  (iv)  $x + \frac{1}{2}, -y + \frac{1}{2}, z + \frac{1}{2};$  (v) x + 1, y, z.

The H atoms attached to O and N atoms were located in a difference map and refined freely. Other H atoms were placed in geometrically calculated positions, with C-H = 0.93 or 0.97 Å, and refined as riding atoms, with  $U_{iso}(H) = 1.2U_{eq}(C)$ .

Data collection: *SMART* (Bruker, 1997); cell refinement: *SAINT* (Bruker, 1997); data reduction: *SAINT*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Bruker, 1997); software used to prepare material for publication: *SHELXTL*.





The molecular structure of (I), showing the atom-labelling scheme. Displacement ellipsolids are drawn at the 30% probability level.



#### Figure 2

The packing of (I), viewed along the a axis. Dashed lines indicate hydrogen bonds.

This work was supported by the Scientific Research Foundation of Tianjin University

#### References

- Bruker (1997). SMART (Version 5.06a), SAINT (Version 5.501) and SHELXTL (Version 5.10). Bruker AXS Inc., Madison, Wiscosin, USA.
- Correale, P., Fulfaro, F., Marsili, S., Cicero, G., Bajardi, E., Intrivici, C., Vuolo, G., Carli, A. F., Caraglia, M., Prete, S. D., Greco, E., Gebbia, N. & Francini, G. (2005). *Cancer Chemother. Pharmacol.* 56, 563–568.
- Duschinsky, R., Pleven, E. & Heidelberger, C. (1957). J. Am. Chem. Soc. 79, 4559–4560.
- Heidelberger, C., Chaudhuri, M. S., Danneberg, P., Mooren, D., Duschinsky, R., Schnitzer, R. J., Pleven, E. & Scheiner, J. (1957). *Nature (London)*, **179**, 663–666.

Huang, J., Qu, J.-Q., Wang, L.-F., Liu, Y.-Q., Wang, Y.-Y., Song, Y.-M., Zhang, C.-J. & Zhan, R. (2005). Chem. Pap. 59, 267–270.

Qu, J.-Q., Huang, J., Wang, L.-F. & Sun, G.-C. (2001). Chem. Pap. 55, 319-322.

Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany. Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.

Tada, M. (1975). Bull. Chem. Soc. Jpn, 48, 3427-3428.

Wang, L.-F., Yang, Z.-Y., Peng, Z.-R., Cheng, G.-Q., Guo, H.-Y., Sun, A.-L., Wang, Q. & He, F.-Y. (1993). J. Coord. Chem. 28, 167–172.
Wasterack, C. & Bettina, H. (1987). Pharmazie, 12, 73–75.